2,4 Dienoyl-CoA reductase deficiency
Editor-In-Chief: Prab R Tumpati, MD
Obesity, Sleep & Internal medicine
Founder, WikiMD Wellnesspedia &
W8MD's weight loss doctor NYC
Philadelphia GLP-1 weight loss and GLP-1 clinic NYC
| 2,4-Dienoyl-CoA reductase deficiency | |
|---|---|
| File:Dienoyl-CoA reductase reaction cis.svg | |
| Synonyms | DECR deficiency |
| Pronounce | N/A |
| Specialty | Medical genetics |
| Symptoms | Hypotonia, developmental delay, seizures, metabolic acidosis |
| Complications | N/A |
| Onset | Infancy |
| Duration | Lifelong |
| Types | N/A |
| Causes | Mutations in the DECR1 gene |
| Risks | Genetic predisposition |
| Diagnosis | Genetic testing, metabolic screening |
| Differential diagnosis | Other fatty acid oxidation disorders |
| Prevention | N/A |
| Treatment | Dietary management, supportive care |
| Medication | N/A |
| Prognosis | Variable, depending on severity |
| Frequency | Rare |
| Deaths | Not commonly reported |
2,4 Dienoyl-CoA Reductase Deficiency is a rare metabolic disorder that affects the breakdown of certain fatty acids in the body. This condition is caused by a deficiency in the enzyme 2,4-dienoyl-CoA reductase, which is essential for the beta-oxidation of unsaturated fatty acids.
Pathophysiology[edit]
The enzyme 2,4-dienoyl-CoA reductase plays a critical role in the mitochondrial beta-oxidation pathway, specifically in the metabolism of unsaturated fatty acids with double bonds at even-numbered positions. In individuals with this deficiency, the inability to properly metabolize these fatty acids leads to the accumulation of intermediate metabolites, which can be toxic and disrupt normal cellular function.
Clinical Presentation[edit]
Patients with 2,4 dienoyl-CoA reductase deficiency typically present with symptoms in infancy or early childhood. Common clinical features include:
Diagnosis[edit]
Diagnosis of this condition is based on clinical presentation, biochemical testing, and genetic analysis. Biochemical tests may reveal elevated levels of unsaturated fatty acids and their derivatives in the blood and urine. Genetic testing can confirm mutations in the gene encoding the 2,4-dienoyl-CoA reductase enzyme.
Treatment[edit]
Management of 2,4 dienoyl-CoA reductase deficiency involves dietary modifications to limit the intake of unsaturated fatty acids and supplementation with medium-chain triglycerides (MCTs), which can be metabolized through an alternative pathway. Supportive care and monitoring for complications such as cardiomyopathy are also important aspects of treatment.
Prognosis[edit]
The prognosis for individuals with 2,4 dienoyl-CoA reductase deficiency varies depending on the severity of the enzyme deficiency and the effectiveness of dietary management. Early diagnosis and intervention can improve outcomes and quality of life.
